Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Terminated 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × peginterferon alfa-2b × Dermatologic × Clear all
NCT00746746 2011-01-13

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Ochsner Health System

Phase 2 Unknown
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡